| Synonyms: | |
| Status: | Phase 2 |
| Entry Type: | Small molecule |
| Molecule Category: | UNKNOWN |
| UNII: | 56R994WX4L |
Physicochemical Descriptors
| Property Name | Value |
|---|---|
| Molecular Formula | C21H20FN7 |
| Molecular Weight | 389.44 |
| AlogP | 4.33 |
| Hydrogen Bond Acceptor | 7.0 |
| Hydrogen Bond Donor | 2.0 |
| Number of Rotational Bond | 6.0 |
| Polar Surface Area | 80.55 |
| Molecular species | None |
| Aromatic Rings | 4.0 |
| Heavy Atoms | 29.0 |
Pharmacology
| Action | Mechanism of Action | Reference |
|---|---|---|
| INHIBITOR | Tyrosine-protein kinase JAK2 inhibitor |
| Targets | EC50(nM) | IC50(nM) | Kd(nM) | Ki(nM) | Inhibition(%) | |
|---|---|---|---|---|---|---|
|
Enzyme
Kinase
Protein Kinase
TK protein kinase group
Tyrosine protein kinase JakA family
|
- | 0.27-41 | 4-4.5 | - | - | |
|
Enzyme
Kinase
Protein Kinase
TK protein kinase group
Tyrosine protein kinase JakB family
|
- | 0.27-41 | 4-4.5 | - | - | |
|
Enzyme
Transferase
|
- | - | - | - | 8.992 | |
|
Epigenetic regulator
Eraser
Histone deacetylase
HDAC class IIb
|
- | - | - | - | 2.35-3.96 |
Indications
| Mesh Heading | Maximum Phase | Mesh ID | Reference |
|---|---|---|---|
| Primary Myelofibrosis | 1 | D055728 | ClinicalTrials |
| Primary Myelofibrosis | 1 | D055728 | ClinicalTrials |
Cross References
| Resources | Reference |
|---|---|
| CAS NUMBER | 1239358-86-1 |
| ChEMBL | CHEMBL3545217 |
| FDA SRS | 56R994WX4L |
CONTENTS